CDK6 and neuroblastoma: Clinically actionable alterations known to be recurrent in NB were found: MYCN amplification (n = 3, 16%) [2], CDK6 or CCND1 over-expression (n = 3, 16%) [34–36], ATRX loss (n = 3, 16%) [37], ALK point mutations (n = 2, 11%) [5] and MDM2 amplification (n = 1, 5%) [38].